Inhibrx Biosciences, Inc. INBX Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $161.66M+30.1% | $124.22M-18.9% | $153.09M-17.9% | $186.57M-13.8% | $216.52M+41.9% | ||
| $171.34M+29.0% | $132.83M-17.7% | $161.42M-16.8% | $193.96M-13.2% | $223.39M+39.3% | ||
| $3.2M-14.4% | $3.73M-13.3% | $4.31M-11.9% | $4.89M-11.9% | $5.55M-10.5% | ||
| $183.97M+25.6% | $146.48M-17.5% | $177.47M-16.3% | $212.12M-12.6% | $242.64M+34.2% | ||
| $8.76M+47.4% | $5.94M-12.2% | $6.77M-18.3% | $8.29M-6.7% | $8.89M-3.8% | ||
| $26.51M-21.6% | $33.8M-6.1% | $35.98M-7.6% | $38.94M-10.8% | $43.64M+7.1% | ||
| $174.99M+74.0% | $100.56M+0.6% | $99.92M+0.6% | $99.28M+0.6% | $98.65M— | ||
| $205M+48.0% | $138.49M-1.5% | $140.64M-2.0% | $143.56M-3.1% | $148.2M+214% | ||
| 120M0.0% | 120M0.0% | 120M0.0% | 120M0.0% | 120M+11,999,900% | ||
| -$279.63M-13.6% | -$246.19M-15.4% | -$213.35M-19.8% | -$178.1M-19.2% | -$149.44M-40.8% | ||
| -$21.04M-363% | $7.99M-78.3% | $36.83M-46.3% | $68.56M-27.4% | $94.44M-29.3% | ||
| $183.97M+25.6% | $146.48M-17.5% | $177.47M-16.3% | $212.12M-12.6% | $242.64M+34.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Inhibrx Biosciences, Inc.'s total assets?
- Inhibrx Biosciences, Inc. (INBX) holds $184.0M in total assets, down 24.2% year over year.
- How much debt does Inhibrx Biosciences, Inc. have?
- Inhibrx Biosciences, Inc. carries $180.9M in total debt against -$21.0M of shareholders' equity, a debt-to-equity ratio of 13.39.
- How much cash does Inhibrx Biosciences, Inc. have?
- Inhibrx Biosciences, Inc. holds $161.7M in cash and equivalents.
- Can Inhibrx Biosciences, Inc. cover its short-term obligations?
- Its current ratio is 6.46 — current assets exceed current liabilities.
- Where does Inhibrx Biosciences, Inc.'s balance sheet data come from?
- Every line is extracted from Inhibrx Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
